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Abstract
Inflammatory bowel diseases such as ulcerative colitis represent serious health burdens, both
because of the tissue-damaging disease itself, and because of an elevated risk of colon cancer. The
increased expression of many members of the matrix metalloproteinase (MMP) family of enzymes
that occurs in colitis, has long been associated with the destructive nature of the disease. Recent
findings in cancer and other MMP-associated diseases, however, led us to question whether
MMPs are indeed detrimental in the setting of colitis. Here, we focus on a single MMP family
member, MMP10, and assess its role in a murine model of colonic tissue damage induced by
dextran sulphate sodium (DSS) treatment. Using mice genetically deficient for MMP10, we find
that absence of this enzyme leads to significantly worse disease scores and failure to resolve
inflammation even after extended recovery periods. We show that MMP10 is produced
predominantly by infiltrating myeloid cells in both murine and human colitis. Through bone
marrow transplant experiments, we confirm that bone marrow-derived MMP10 contributes to
colitis severity. Mice lacking MMP10 have a significantly higher propensity for development of
dysplastic lesions in the colon after two rounds of DSS exposure. Thus, we conclude that MMP10
is required for resolution of DSS-induced colonic damage, and in its absence, chronic
inflammation and ultimately dysplasia occurs.
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Inflammatory bowel disease (IBD) affects approximately 2 million people in the US alone.
Ulcerative colitis (UC), one of the most common manifestations of inflammatory bowel
disease, is characterized by chronic relapsing inflammation of the large bowel that spreads
from the rectum toward the colon-ileal junction. Clinical symptoms include diarrhea, rectal
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bleeding, passage of mucus, urgency, and abdominal pain (1). UC produces significant
morbidity in affected individuals through the burden of its clinical symptoms and by
increasing patients’ risk of colorectal cancer (2). HistoIogically, UC is characterized by
inflammatory cell infiltration, epithelial cell destruction, and continuous mucosal
inflammation and ulceration that spread proximally from the rectum. Currently, UC is
without a cure and treatment involves the administration of disease modifying agents that
often carry substantial side-effects (3). Surgical treatment is also not without significant
morbidity including infection, infertility, sexual dysfunction and fecal incontinence. Ideally,
a treatment of UC would induce and maintain remission, promote mucosal healing, avoid
surgical intervention, and reduce cancer risk (4).
Matrix metalloproteinases (MMPs) initially presented an attractive target for IBD treatment
because ulcer biopsies from patients with IBD had high levels of several enzymes including
MMPs-1,3,7,9, 10 and 12 (5–9). In humans, MMPs are a family of 24 proteases with unique
zinc-containing catalytic domains. While there were several favorable reports on the use of
synthetic MMP inhibitors in murine colitic damage induced with dextran sodium sulfate
(DSS) or trinitrobenzensulfonic acid (TNBS) (10, 11), the clinical use of MMP inhibitors
fell into disfavor when human cancer trials using MMP inhibitors had negative results (12).
The roles of MMPs in human disease were reappraised following the disappointing cancer
trials. It became clear that MMPs had more diverse, complex functions than previously
believed. In addition to matrix proteins, chemokines, cytokines, receptors and antimicrobial
peptides are now recognized as in vivo substrates for MMPs (13, 14). The connection
between MMP expression and IBD is well established, but how MMP function may be
detrimental or beneficial in the course of the disease has remained unclear. A large part of
the complexity stems from the myriad roles that MMPs may play in vivo.
Here we focus on one particular MMP, MMP10, also known as stromelysin-2. MMP 10 is a
rational target for investigation in IBD because its expression has been described at healing
ulcer edges in human specimens of UC (8). As is the case for many MMPs, the timing of
MMP10 expression associates it with disease pathophysiology. However, the reported
localization of human MMP10 to healing edges suggests a possible role in disease resolution
rather than disease progression. Thus, we used Mmp10−/− mice to ask whether MMP10
plays a beneficial or detrimental role in colonic injury using the dextran sulfate sodium
(DSS) model. Further, we investigate the consequences of MMP10 ablation on the most
serious long-term outcome of chronic colonic injury, i.e. neoplasia.
Materials and Methods
Mice
Breeding pairs of Mmp10−/− mice, on the C57BL/6 background were transferred from
University of Washington and used to establish colonies in both a specific-pathogen-free
room (after re-derivation at Jackson Labs) and in regular mouse-housing. Similarly, C57BL/
6j control mice were purchased from Jackson Labs (Bar Harbor, ME) and used to establish
breeding colonies with housing in cages directly adjacent to the Mmp10−/− colony. For all
colitis experiments, 8-week old male mice were used, as female mice showed greater
variation in the response to DSS (as has been reported (15)). Prior to initiation of our
studies, all animal experiments were approved by the local Institutional Animal Care and
Use Committee.
Experimental colitis model
A 2.5% aqueous solution of DSS (M.W. = 36,000–50,000; MP Biochemicals, Solon, OH)
was provided ad libitum to the mice in water bottles for 7 days. The amount of DSS solution
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in the bottles was recorded daily to ensure similar exposures for all cages. After 7 days,
cohorts of mice were immediately euthanized (7 day), returned to regular water for 3 days,
then euthanized (10 day), returned to regular water for 7 days, then euthanized (14 day), or
returned to regular water for 14 days before being euthanized (21 day). All mice were
weighed daily from the first day of DSS exposure to euthanasia.
Chronic colitis
To induce a chronic colitis, mice were put through 2 separate 4-day exposures to 3% DSS
that were 16 days apart. The mice were maintained for a further 4 weeks prior to euthanasia.
Bone marrow transplants
All bone marrow transplant experiments were performed with mice in the specific pathogen-
free barrier facility. Bone marrow was harvested from the femurs of 4-week old donor
female mice, either control C57BL/6 or Mmp10−/−, and rinsed twice in sterile PBS. The
bone marrow cells were counted and diluted with sterile PBS to a concentration of 2 ×107
cells per ml. 5-week old recipient male mice were lethally irradiated using a split dose
regimen with two doses of 4 Gy given 4 hours apart, using an RS2000 Xray irradiator
(RadSource, Suwanee, GA). Three hours after the second radiation dose, the mice received 2
×106 donor bone marrow cells injected intravenously via the tail vain. Recipient mice were
weighed daily for the first week following transplant and weekly thereafter until 4 weeks
post-transplant. They were then administered 2.5% DSS for 7 days as described previously,
switched to regular water for a 3-day recovery period and then euthanized.
Histology and Scoring
Colons were removed from euthanized mice, rinsed with PBS, then cut open longitudinally,
before being rolled into ‘Swiss rolls’. The Swiss rolls were held together with a 30 gauge
needle, fixed in 10% formalin and embedded in paraffin. 5µm sections of the paraffin-
embedded tissue were cut and stained for basic histology using hematoxylin and eosin (H &
E) and periodic acid Schiff (PAS) stains, all purchased from Sigma (St Louis, MO).
A colitis damage score was generated from digital images of PAS-stained sections, by firstly
measuring the distance around the intact muscularis using the AVP Universal Desktop Ruler
software. The areas of ulceration were then measured and given the following scores: 1=1/3
of the bottom of the crypt injured, 2= 2/3 of the bottom of the crypt injured, 3= total crypt
loss but epithelial lining remains, 4 =crypt and epithelial loss. The ulceration was graded
according to the worst area. Then, the ulceration score was multiplied by the length of
involved colon. The individual ulceration scores were then summed and divided by the total
colon length to give a measure of ulceration severity/unit colon. The percentage of colon
scored per grade for each mouse was calculated and used to allow comparison of the spread
of grades between genotypes.
Immunohistochemistry
Two different human colon tissue microarrays, both containing some specimens of human
IBD were purchased from US Biomax (Rockville, MD). For mouse tissues, formalin-fixed
paraffin-embedded 5µm sections were used. The slides were dewaxed, rehydrated, and
treated with hydrogen peroxide to quench endogenous peroxidases. After heat-mediated
antigen retrieval using 10mM sodium citrate, pH 6.0, the slides were blocked for 1 hr with
5% goat or rabbit serum and then incubated overnight with a rabbit polyclonal anti-human
MMP10 antibody (Abcam, Cambridge, MA), or a rat anti-mouse neutrophil antibody
(Serotec, Raleigh, NC), or a rat anti-mouse F4/80 antibody (Serotec). The following day, the
slides were washed with Tris-buffered saline and incubated with biotinylated anti-rabbit or
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anti-rat antibodies (Vector Laboratories), before being incubated with Vectastain ABC
reagent (Vector Laboratories, Burlingame, CA) following manufacturer’s instructions. The
chromogen diaminobezidine (DAB; Sigma) was used to visualize positive antibody binding,
and the slides were counter-stained with Mayer’s hematoxylin prior to clearing and
mounting. Quantification of positive signals from the neutrophil and macrophage
immunostaining was done using Metamorph software on images taken with a 20× objective
lens with a Zeiss Axiophot microscope, as previously described.
Immunofluorescence
Colon from mice treated for 7 days with 2.5% DSS was harvested, rinsed, split open, rolled,
covered with OCT freezing medium and quick frozen in liquid nitrogen. 8 micron sections
were cut onto glass slides, and rinsed in PBS before fixing in acetone for 5 min and then
blocking with Image-iT FX signal enhance reagent (Life Technologies, Carlsbad, CA) for
30 min followed by 10% goat serum for 15 min. The slides were incubated for 2 hr at room
temperature with rat anti-F4/80 (Serotec) and/or rabbit anti-MMP10 (Novus Biologicals,
Littleton, CO) in 10% serum. After washing, the slides were incubated with AlexaFluor488
anti-rat and AlexaFluor594 anti-rabbit antibodies (Life Technologies) for 30 minutes. After
repeated washing and a 2 minute incubation in 0.5 µg/ml Hoechst 33258 (Sigma) diluted in
PBS, the slides were mounted using Prolong Gold Anti-Fade (Life Technologies). The slides
were examined with a Zeiss Axiophot microscope and 20× objective lens images captured
with a Hamamatsu camera using Metamorph software.
In situ hybridization
A 750bp sequence of mouse MMP10 (16) carried in the pGem4mStr2 plasmid, a gift from
Dr Lynn Matrisian, Vanderbilt University, was labeled, according to manufacturer’s
instructions using the Dig T7/Sp6 labeling kit (Roche Applied Bioscience, Indianapolis, IN)
to produce sense and antisense probes. 5-micron paraffin sections of Swiss-rolled colons
from control or DSS-exposed wild-type and Mmp10−/− mice were dewaxed, rehydrated then
post-fixed in 4% paraformaldehyde. The sections were digested with 10 µg/ml proteinase K
for 20 minutes, then immersed in 0.2N HCl for 1 hour to quench endogenous alkaline
phosphatase activity. Following 10 minute immersions in 0.1M triethanolamine and 0.1M
triethanolamine/0.25% acetic acid, to inhibit electrostatic interactions, the sections were air-
dried for several hours. For hybridization, sense or antisense probes diluted to 1.5 ng/ml
with hybridization buffer (Dako Cytomation, Ventura, CA) were placed on individual
sections in a humid chamber. Each section was covered with a hybri-slip (Sigma), and the
chamber incubated at 50°C for 16 hours. Following hybridization, the slides were washed in
three changes of 2X SSC/50% formamide at 50°C, then in 2X SSC at room temperature.
The presence of probe was detected using an alkaline phosphatase-labeled anti-digoxigenin
antibody (Roche) that was incubated with the sections for 2 hours, according to
manufacturer’s recommendations. Following washing, colorimetric signal was developed
using the substrates BCIP and NBT (Promega, Madison, WI).
Quantitative PCR
Isolation and analysis was performed as previously described (17). Briefly, total RNA was
isolated using Trizol (Invitrogen, Carlsbad, CA) and used to generate cDNA with a High
Capacity cDNA archive kit (Applied Biosystems, Foster City, CA). 5 µg of the cDNA was
mixed with primers and FAM-labeled Taqman probes for MMP10 and GAPDH, and
product was measured using an ABI- HT7900 Fast Real-Time PCR system. The threshold
cycle (Ct) was obtained from duplicate samples and averaged, and the Ct range for each is
shown in the figure legends. The ΔCt was the difference between the average Ct for the
specific cDNAs and the average Ct for GAPDH, which ranged from 16.97 to 14.16. The
ΔΔCt was the average ΔCt at a given time point minus the average ΔCt of day-0 samples.
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The data are expressed as relative quantification (RQ), which is the fold change and
calculated as 2−ΔΔCt. For measurement of macrophage markers, specific Quantitect primers
for Nos2 (INOS), Cxcl10, Ccl3, Chi3l3 (Ym1), Retnla (FIZZ), Arg1 (arginase) and Gapdh
were obtained from Qiagen and transcripts were detected using SYBR Green that had been
included in the QuantiFast reaction mixture (Qiagen). Analysis was performed as above.
In vivo permeability measurement
An 80mg/ml solution of FITC-dextran (4000 MW; Sigma) was prepared with sterile saline
and administered to 5 each control and Mmp10−/− mice after 0 or 3 days of 2.5% DSS
treatment by oral gavage at a dose of 600 mg/Kg. Four hours later, serum was collected
from the gavaged mice and assayed using a fluorometric plate reader (Victor3 Multi-Label
Counter, Perkin-Elmer) for levels of green fluorescence from the FITC-dextran.
Evaluation of cytokines and chemokines
Multi-array ELISA plates for both cytokines and chemokines were purchased from SA
Biosciences (Frederick, MD). Pooled plasma or colonic lavage fluid from 3 each control or
Mmp10−/− mice collected at 0, 4-days or 8-days post initiation of DSS exposure were used
for these assays, which were performed according to the manufacturer’s instructions. Only
those cytokines/chemokines that showed differences between the control and Mmp10−/−
groups were evaluated further. Single analyte ELISAs for the cytokines IL1, IFNγ, G-CSF
and TNF, and the chemokine MCP-1 were purchased from SA Biosciences. Plasma or
lavage fluid from individual mice collected 0,4 or 8-days post initiation of DSS-exposure
were analyzed following manufacturer’s recommendation.
Macrophage cell culture
RAW264.7 murine monocyte cells were obtained from American Tissue Culture Collection
(ATCC, Rockville, MD) and maintained as recommended in Dulbecco’s modified Eagles
medium (DMEM; Life Technologies) containing 10% fetal calf serum. For activation in
vitro, the cells were treated with 10 ng/ml lipospolysaccharide (LPS; Sigma) plus 100 IU/ml
interferon-γ (R&D Systems, Minneapolis, MN) or 10ng/ml interleukin-4 (IL4; Life
Technologies) plus 10 ng/ml interleukin-13 (IL13; Life Technologies) for 24 hours as
previously described (Zhang).
Results
MMP-10 mRNA expression is increased in mice exposed to DSS
MMP10 is expressed by ulcer-edge enterocytes and cells within granulation tissue in human
ulcerative colitis (8, 18). To assess possible function of this enzyme in colitic disease, we
first determined when MMP10 is expressed in a mouse model of acute colitis. Mice were
exposed to 2.5% dextran sulfate sodium (DSS) provided ad libitum in drinking water for a
period of 7 days, and then returned to regular drinking water. At days 0, 7, 10, 14, 21 and 28
post-initiation of DSS, groups of mice were euthanized, and RNA prepared from the colonic
tissue. As can be seen in Fig 1A, MMP10 expression was low to absent in normal colonic
tissue, rose to peak expression at the end of the DSS treatment and then gradually returned
to control levels. Based on Ct values greater than 35, we conclude that MMP10 was not
expressed in normal colon but was induced in response to acute colon injury, and that
expression is turned off once the tissue has repaired and inflammation has resolved. Semi-
quantitative reverse-transcription PCR using a different set of primers confirmed these
results (data not shown).
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Infiltrating cells are responsible for the majority of MMP10 seen in murine and human
inflammatory bowel disease
Animals exposed to 2.5% DSS predictably developed colitic damage and associated
inflammation, which was histologically confirmed by crypt loss as well as infiltration of a
large number of cells. Since we found antibodies to mouse MMP10 to be unreliable for
immunohistochemistry in paraffin sections, we used in situ hybridization to identify the cell
types responsible for the production of MMP-10 in colitic areas. The strongest positive
signal was seen in infiltrating cells surrounding the bottom of crypts (Fig 1B). To ascertain
whether such expression was limited to the DSS acute colitis model, we also stained sections
from interleukin-10 null mice, which develop spontaneous chronic inflammatory bowel
disease (19). As can be seen in Fig 1C, there was a similar pattern of MMP10 positivity in
infiltrating cells within colonic lesions. To determine whether the pattern of expression was
similar in human inflammatory bowel disease, we examined archival de-identified human
colon tissue specimens from IBD patients. While there was some evidence of epithelial
expression as reported in earlier literature (18), by far the strongest expression was in
inflammatory cells (Fig 1D). Overall, 6 out of 15 sections showed MMP10 staining in
epithelial cells, 13 out of 15 showed MMP10 staining in inflammatory cells and 2 out of 15
had no detectable MMP10. To determine whether the MMP10-expressing cells were
macrophages, as suggested by morphology, we used a double-staining immunofluorescent
procedure on frozen sections of colon tissue from mice that had been exposed to 2.5% DSS
for 7 days. As shown in Fig 1E, the majority of the MMP10-positive cells in the sub-crypt
area also stained for the macrophage marker F4/80.
MMP-10 null mice have more severe DSS colitis
To determine the functional significance of MMP10 in acute colitis, we placed cohorts of
wildtype and Mmp10−/− mice on DSS treatment for 7 days, then allowed subgroups of each
genotype to heal for different periods of time (Fig 2A). To measure the severity of DSS
colitis, we monitored weight loss, colon length, and histologic score. Mice consistently
reached the nadir of their weight loss at 8–10 days post DSS-initiation (Fig 2B). At the 10
day time point the weight loss of the Mmp10−/− mice was significantly worse in the 10, 14
and 21 day groups. Notably, we observed no difference in either starting weight or colon
lengths between control Mmp10−/− and wildtype mice not exposed to DSS (Supplemental
Fig 1A, B). Colon shortening, a morphometric measure of inflammation was more severe in
the Mmp10−/− mice (Supplemental Fig 2). Ulceration scores, generated from histological
assessment, showed significant differences in the amount of severe, grade 4 ulceration in the
Mmp10−/− mice compared to wild-type controls (Fig 2C). In wildtype mice, there was
almost complete resolution of histological damage to the colon by day 21 i.e. 14 days after
discontinuation of the DSS. In contrast, significant tissue damage remained evident in
Mmp10−/− mice at this timepoint.
Basal proliferation and intestinal permeability is normal in Mmp10−/− mice
Mmp10−/− animals do not have any gross phenotypic abnormalities and reproduce normally
(20). The general appearance of their colons and presence of inflammatory cells did not
differ from wildtype mice (data not shown). Since it has been reported that mice deficient in
a related enzyme, MMP2, appear to have a defect in barrier function in the gut (21), we
assessed gut permeability directly. To do this, cohorts of wildtype and Mmp10−/− mice
received a dose of FITC-dextran by oral gavage. After 4 hours, serum was collected from
the gavaged mice and the levels of FITC measured using a plate fluorometer. As anticipated
from the lack of baseline inflammation, permeability did not differ between control wildtype
and Mmp10−/− mice (Supplemental Fig 3A). Notably, the permeability was increased after 3
days of exposure to 2.5% DSS but was still not significantly different between the two
strains of mice (Supplemental Fig 3B). Immunohistochemical staining of the colonic tissue
Koller et al. Page 6
Lab Invest. Author manuscript; available in PMC 2013 June 01.
$watermark-text
$watermark-text
$watermark-text
also demonstrated that untreated Mmp10−/− and wildtype animals have no difference in the
number of dividing cells identified by phosphohistone-3 immunostaining (data not shown).
Thus, we concluded that the differences seen following DSS exposure were not due to
baseline differences between wildtype and Mmp10−/− mice.
Leukocyte infiltration was increased in MMP10- null mice
To better characterize the infiltrating cell populations in the colonic lesions that developed
after DSS exposure, we immunostained colon sections with anti-neutrophil antibody.
Although at day 7 we observed fewer neutrophils in Mmp10−/− colons, at days 10 and 14
there was a trend for greater neutrophils in Mmp10−/− mice compared to wildtypes (Fig.
3A). More strikingly, at day 21, when neutrophilia had largely resolved in wildtype mice,
elevated numbers of neutrophils persisted in the colons on Mmp10−/− mice (Fig. 3A). In
contrast, there was a significantly higher level of macrophages at day 7 in the MMP10-null
samples, coincident with the peak expression of MMP10 seen in wildtype mice (Fig. 1A).
Intriguingly, at day 21, although there were still large lesions visible in the Mmp10−/−
tissues, staining for F4/80+ macrophages was undetectable, similar to the situation in the
healed wildtype colons. Since macrophages can be activated to different functional states,
and there are suggestions that alternatively activated (M2) macrophages are important in
resolution of DSS-induced damage, we assessed levels of macrophage activation markers.
Whole colons were isolated from 5 each wildtype and Mmp10−/− mice that had been
exposed to 2.5% DSS for 7 days, then given one day to start recovery. Levels of transcripts
for the classically activated (M1) macrophage markers INOS, CXCL3 and CCL10, as well
as for the alternative activation (M2) macrophage markers mannose receptor, Ym1 and FIZZ
were determined using real-time PCR analysis of RNA from the colon tissue. The
combination of these markers for macrophage phenotyping has been described in the
literature (22, 23). As can be seen in Fig 3C, the relative levels of M1 markers were
increased while M2 markers were decreased in the colonic tissue from DSS-treated
Mmp10−/− mice.
Cytokine profiles of colonic lavage correlate with severity of colitis
Since MMP10 was primarily produced by inflammatory cells during DSS-induced colitis,
we reasoned that MMP10 may play a role in cytokine release. To assess whether levels of
secreted cytokines were different between wildtype and Mmp10−/− mice, colonic lavage
fluid was collected from mice that had been exposed to 3–4 or 7 days of DSS. The 7 day
exposure group was given 1 additional day on regular water to allow the repair process to
begin before samples were collected on day 8. Samples were also collected from mice that
were never exposed to DSS. Levels of cytokines were then assessed as detailed in Materials
and Methods. Levels of IL-1A, TNFα, and G-CSF were significantly increased in MMP10-
null animals 8 days after initial exposure to DSS compared to the wildtype counterparts,
however, we saw no difference in levels of any cytokine between genotypes at earlier
timepoints (Fig 4A–C). In addition, the levels of other factors assayed (ILs-1b, -2, -4, -6,-10,
-12, -17a; Interferon-γ; or GM-CSF) did not differ between wildtype and Mmp10−/− at
baseline or either experimental timepoint (data not shown). Thus the higher levels of
specific pro-inflammatory cytokines at the late timepoint in the Mmp10−/− mice were most
likely related to a failure to resolve on-going inflammation.
Since there was an apparent difference in the number of infiltrating leukocytes in the colitic
lesions of DSS-treated Mmp10−/− mice compared to controls, we also assessed levels of
chemokines both in the local environment, by testing colonic lavage, and systemically in the
blood. Only one chemokine, macrophage chemoattractant protein-1 (MCP-1/CCL2) differed
between wildtype and Mmp10−/− mice, with elevated levels in null mice at both early and
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late stages of disease, suggesting that it may have a functional role in inducing the
exacerbated inflammatory response (Fig 4D).
Bone marrow transplant suggests marrow genotype contributes to severity of colitis
The identification of infiltrating cells, particularly macrophages, as the predominant cellular
source of MMP10 prompted us to investigate whether the more severe colitic phenotype of
the Mmp10−/− mice was dependent only on bone marrow cells. We lethally irradiated
matched cohorts of control and Mmp10−/− animals and repopulated with donor marrow from
healthy control or Mmp10−/− mice. After a 4-week period of reconstitution, we challenged
recipient mice with a seven-day course of 2.5% DSS and then euthanized mice one day after
the DSS treatment ended. Analysis of weights showed no significant differences amongst
the groups (Fig 5A). Histological analysis, however, indicated that the extent of grade 4
severe lesions was associated predominantly with the genotype of the bone marrow supplied
in Mmp10−/− but not wildtype recipient mice (Fig 5B). It is important to note that these
experiments were conducted in a specific pathogen-free barrier facility, where the severity
of DSS-induced colitis was reduced in all animals compared to their counterparts in normal
housing. Overall, these results suggest that bone marrow-derived MMP10 contributes to
amelioration of colitis severity, but other cellular sources present in wild-type mice are also
important.
Incidence of dysplasia is increased in Mmp10−/− mice
In order to determine whether lack of MMP10 altered colitis-associated cancer development,
we attempted to induce chronic colitis by repeated exposure to DSS. Previous literature
demonstrated that 4 rounds of DSS exposure result in chronic colitis in C57BL/6 mice (24).
However, severe morbidity that reached the criteria for euthanasia occurred in the
Mmp10−/− mice after only 2 rounds of DSS, barring any further exposure. Thus, we treated
cohorts of wild-type and Mmp10−/− mice with two 4-day rounds of 3% DSS, 3 weeks apart,
and let the animals recover for a further 3 weeks before termination. We then isolated the
colons and examined them histologically. As expected, the degree of dysplasia in the wild-
type mice after only 2 rounds of DSS was very low. In Mmp10−/− mice, however, the
frequency of dysplasias detected was significantly elevated (6/8 (75.0%) in Mmp10−/−
versus 1/7 (14.3%) in wildtype; p = 0.04, Chi-square test). Examples of the lesions detected
in Mmp10−/− mice are shown in Fig 6.
Discussion
Here we have used the DSS model of acute intestinal damage and inflammation to
investigate functions of the proteinase MMP10. Although MMP10 expression was induced
in response to colon injury, our data indicate that this proteinase functions more in disease
resolution than progression. Mice lacking MMP10 were clearly deficient in their ability to
effectively heal mucosal ulcers. These results lead us to characterize MMP10 as playing a
beneficial/protective role in the DSS-induced colitic damage model, and suggest that
strategies to enhance MMP10 rather than inhibit its activity may have therapeutic impact.
One difficulty with testing possible molecular mechanisms for IBD and associated
therapeutic strategies is the paucity of models that can truly recapitulate the complexity of
human disease. Nevertheless, particular aspects of the disease process such as immune cell
dysregulation or epithelial damage can be examined using the IL-10−/− mouse (19),
transplantation of CD45hi CD4+ T cells into immunosuppressed animals (25) or treatment
with agents such as trinitrobenzenesulfonic acid (TNBS) (26) or dextran sulfate sodium
(DSS) (27), respectively. The DSS model, in particular, is widely used because of the ease
of administration and ability for temporal control (27). The detailed mechanism by which
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DSS induces damages and ensuing acute inflammation has been recently described (28).
One attractive feature of this model is different strains of mice and other rodents are
differentially sensitive to the effects of DSS, reflecting the role that genetic factors have in
human disease (15). Thus, although the DSS model cannot be considered “mouse ulcerative
colitis”, aspects of it are similar and it has been useful in identifying some important
pathways as well as for testing of drugs (27).
A previous report of MMP10 in human inflammatory bowel disease suggested a possible
role in healing, however this was based solely on apparent localization in migrating
epithelial cells (18). Our investigation of MMP10 localization in DSS-injured and IL10-null
mouse colons and in human IBD samples revealed more prominent expression in leukocytes
rather than epithelial cells, a pattern also seen in models of lung infection and injury (WCP,
unpublished observations). From their morphology, the MMP10-positive cells were of a
monocytic origin. In the DSS model, we then confirmed macrophage expression of MMP10
using co-staining with the widely-used murine macrophage marker F4/80 (29). Although
F4/80 is predominantly expressed by macrophages, there can be some expression by
subclasses of dendritic cells and eosinophilic granulocytes, therefore there remains a formal
possibility that myeloid cells other than macrophages express MMP10 in the DSS model.
Our bone marrow transplant experiments support the premise that MMP10 in bone marrow-
derived cells provides a protective response to DSS-induced injury. This is most clearly
shown when the bone marrow is transplanted to Mmp10−/− recipients. Since the effect is not
so clear in wild-type mice, MMP10 from non-bone marrow derived cells must also
contribute to regulation of colitis severity.
As MMPs are often thought of as extracellular matrix-degrading enzymes, it is unsurprising
that they are often thought of as being destructive. Indeed many previous studies of MMPs
in several colitis models have confirmed deleterious functions (10, 11, 30–33). A common
strategy for such studies was the administration of broad-spectrum MMP inhibitor drugs to
experimental animals, and observation of disease modification. However, such an approach
can obfuscate differential roles for individual family members. An alternative approach has
been the use of in vivo administered silencing RNAs (siRNAs) toward individual members.
Such reagents have been used to target both MMP3 and MMP10 in DSS-induced colitis
(34), however the level of knockdown achieved (approximately 50%), the length of time for
which knockdown is achieved, and the unknown penetration of the knockdown into different
cell types means that results are very difficult to interpret. The availability of mouse lines
genetically ablated for specific MMPs has allowed more careful probing of the contributions
of particular enzymes (35). For example, the gelatinases MMP2 and MMP9 appear to have
opposing roles with MMP9 being destructive and MMP2 protective due to effects on
maintenance of intestinal barrier function (21). Protective functions for individual family
members have also been seen in other disease settings such as cancer (36, 37). Indeed, the
same MMP can have both protective and destructive roles that are context-dependent (36).
Together, these findings illustrate that the once popular therapeutic strategy of broad MMP
inhibition is flawed. Our data would suggest that MMP10 inhibition is likely to enhance
disease severity and increase healing time. It remains to be seen if increasing the levels of
MMP10 would have the opposite effect and reduce healing time. If so, this could prove a
valuable tool in minimizing the clinical problems associated with IBD.
One of the most dangerous effects of chronic IBD is the increased risk for colon cancer
development. Colitis-associated colon cancer, while in many ways similar to sporadic colon
cancer, does have some particular characteristics. It is associated with younger age at onset,
a mucinous/signet ring histology, a higher rate of 2 or more synchronous primary tumors,
and a more proximal distribution in the colon (2). In the setting of IBD, cancers are believed
to progress from no dysplasia to “indefinite” dysplasia, to low grade, then high grade
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dysplasia ultimately becoming carcinoma (2). In our studies, a lack of MMP10 resulted in
enhanced development of dysplasia in DSS-treated mice. While we cannot rule out direct
MMP10-mediated changes in epithelial cells, the most likely explanation is that the
unremitting inflammation seen in DSS-treated Mmp10−/− mice is the major cause. In other
mouse models of colon cancer such as ApcMin/+, as well as in human colon cancer
specimens, MMP10 levels are often increased (38, 39), although this is in multiple cell types
including epithelial tumor cells. It is as yet unclear if the enzyme contributes to cancer
progression or if its increased levels are merely an indicator of increased numbers of cancer
cells. Future studies will address possible roles of MMP10 in colorectal cancer development
and progression.
A major question remaining from our studies is the identification of the MMP10 substrate(s)
responsible for its protective function. Since persistent inflammation is the dominant
phenotype associated with MMP10 loss in both this study and in a previously published
Pseudomonas aeruginosa infection model (20), cleavage of a cytokine/chemokine may be
responsible for regulating immune response. MMP-mediated processing of chemokines has
been reported in several systems (14) and other studies have shown MMP-dependent effects
on chemokine compartmentalization (40, 41). Such modifications usually produce proteins
reduced in only a small number of amino acids, so these changes are unlikely to be detected
using ELISA methodologies such as were used here. We did find a change in the circulating
levels of monocyte chemoattractant protein (MCP)-1 at early timepoints post-DSS treatment
that suggest this may be an important effector of the enhanced inflammatory response in
Mmp10−/− mice. It should be noted, however, that there are no apparent disease differences
between the wildtype and Mmp10−/− mice at early timepoints after DSS exposure. Intestinal
permeability is similarly increased between the two genotypes compared to their baseline
counterparts (Supp Fig 3B), and a pilot study assessing histological changes also showed no
quantifiable difference between the genotypes after 4 days of DSS exposure (data not
shown).
While increased inflammation was evident in the DSS-treated Mmp10−/− mice, and
neutrophil numbers were particularly high, the numbers of F4/80-positive macrophages
decreased over time in DSS-treated Mmp10−/− mice compared to the corresponding wild-
type mice. Interestingly, the phenotype of the DSS-treated Mmp10−/− mice is strikingly
similar to one reported by Qualls and colleagues in which macrophages were either
systemically or locally depleted (42). More recently, CX3CR1-deficient mice were shown to
have significant reduction in lamina propria macrophages and have enhanced severity of
DSS-induced colitis (43). Other studies have suggested that macrophages are required for
wound healing in models of colonic damage (44, 45). Finally, there are indications that
alternatively activated or M2 macrophages can be protective against colitis induced by either
TNBS (46) or DSS (47). In our study, not only are macrophage numbers lower in Mmp10−/−
mice, but there appears to be a skewing toward M1 rather than M2 macrophages. Overall
then, the changes in macrophages seen in DSS-treated Mmp10−/− mice are likely
contributing factors to the failure of the healing program in these mice.
In conclusion, the data presented here indicate that MMP10, produced by infiltrating
myeloid cells after DSS-induced colonic damage, plays a role in disease resolution. In the
absence of this enzyme, colonic inflammation persists and eventually results in the
development of dysplastic lesions. Thus, enhancing MMP10 expression may be a
therapeutic strategy worth considering for promotion of mucosal healing.
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Refer to Web version on PubMed Central for supplementary material.
Koller et al. Page 10
Lab Invest. Author manuscript; available in PMC 2013 June 01.
$watermark-text
$watermark-text
$watermark-text
Acknowledgments
We are especially thankful to Dr Mark Frey of the University of Southern California for paraffin sections from Il10-
null mice, to Dr Lynn Matrisian for the MMP10 in situ hybridization probe, and to the Vanderbilt Tissue
Acquisition Core for the archival de-identified human IBD specimens. Additionally, we gratefully acknowledge Dr
M. K. Washington for helpful discussions regarding histology scoring, and Dr J.T.Roland and the Epithelial
Biology Center Shared Imaging Resource for Ariol scanning of slides.
Funding: FLK was supported by training grant T32CA106183. This work was also supported by the Vanderbilt-
Ingram Cancer Center support grant P30CA068485, by pilot funding from the Vanderbilt Digestive Disease
Research Center P30DK058404, and by HL089455 and HL098067 (WCP)
Abbreviations
MMP matrix metalloproteinase
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Fig 1. MMP10 is induced by inflammation in murine and human colonic tissue
(A) Real-time PCR analysis of MMP10 expression in colon tissue of C57BL/6 mice at
different timepoints before, during and after a 7-day treatment with DSS. (B, C) In situ
hybridization for Mmp10 transcript in colon tissue specimens from DSS-treated (B) or
Il10−/− (C) C57BL/6 mice. Antisense and sense probes were both labeled with digoxigenin
and applied at the same concentration. Positive signal is purple (e.g. arrows); nuclei are
counterstained with Fast Red. A higher magnification of the area bounded by a rectangle in
the DSS anti-sense image is shown in the adjacent panel. (D) Immunohistochemical
detection of MMP10 protein in specimens of colon tissue from 2 different IBD patients.
Positive signal is brown; nuclei are counterstained blue with hematoxylin. (E)
Immunofluorescent co-staining of a frozen section of colon from a mouse after a 7-day
treatment with DSS. The murine macrophage marker F4/80 is shown on the left, MMP10 is
shown in the center and merged image showing F4/80 (green), MMP10 (red) and nuclear
stain (blue) is on the right.
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Fig 2. MMP10-deficient mice are significantly more injured by DSS treatment than wildtype
mice
(A) Scheme showing the four timepoints after a 7-day exposure to 2.5% DSS at which
cohorts of mice were analyzed. (B) Average weight change, relative to each individual
starting weight, for all mice on the DSS protocol. Wildtype mice are shown in black,
whereas Mmp10−/− mice are in grey. (C) Histological scores for wildtype (black bars) and
MMP10−/− (white bars) colon sections from mice assessed at the 4 different timepoints
outlined in (A). The description for each of the grades is given in the Materials & Methods.
Shown is the average percentage of the colon length assessed at each grade for each group
of mice.
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Fig 3. Leukocyte recruitment is altered in DSS-treated MMP10-deficient mice
(A) The average level of PMN immunostaining per unit area of colonic tissue in widltype
(black bars) or MMP10−/− (white bars) mice at each of the 4 timepoints after DSS
treatment. (B) The average number of F4/80-positive macrophages per unit area of colon
tissue from wild-type (black bars) or MMP10−/− (white bars) mice at 3 timepoints after DSS
treatment. Macrophages were undetectable at 21 days. (C) Whole colon lysates from 7-day
DSS-treated mice were analyzed by realtime PCR for markers of macrophage activation
status. Shown are the levels of markers of M1 macrophages (INOS, CXCL3 and CCL10)
and M2 macrophages (mannose receptor, Fizz and Ym1) in MMP10-null colons compared
to levels in wild-type colons after normalization using levels of GAPDH.
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Fig 4. Bone marrow transplant experiments suggest colitis severity is largely controlled by bone
marrow-derived MMP10
(A) Weight changes over the course of DSS treatment and 3-day recovery. Black symbols
indicate wildtype recipients, while grey indicates MMP10−/− recipients. Filled circles
indicate wildtype donors, while empty circles indicate MMP10−/− donors. (B) Histologic
grades of colonic tissue specimens from bone marrow transplant mice. The dark bars on the
left indicate wildtype recipients, while the light bars on the right are MMP10−/− recipients.
Solid bars are wildtype donors and hashed bars are MMP10−/− donors. The grades (assigned
as described in Materials & Methods) are indicated by G1 through G4, with the bars
representing the average percentage of colon length calculated for each grade in each group
of mice.
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Fig 5. Levels of cytokines and chemokines detected by ELISA in fluids from DSS-treated mice
Levels of IL1a (A), G-CSF (B), and TNFα (C) measured in colonic lavage samples
collected from mice on day 4 or day 8 of a 7-day DSS treatment protocol. Day 8 mice had
one recovery day before collection. (D) Levels of the chemokine MCP-1 detected in serum
from mice on day 3 or day 8 of a 7-day DSS treatment protocol.
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Fig 6. Dysplastic lesions are present in the colons of MMP10−/− mice after two rounds of DSS
treatment
Shown are examples of hematoxylin and eosin-stained lesions from 3 different MMP10−/−
mice. Boxed regions showing examples of dysplasic lesions are shown in higher
magnification on the right. Scale bar = 100 µm.
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